Abstract:Introduction: Antimicrobial resistance is a growing health problem. Pseudomonas aeruginosa is a pathogen of major concern because of its multidrug resistance and global threat, especially in health-care settings. The pathogenesis and drug resistance of P. aeruginosa depends on its ability to form biofilms, making infections chronic and untreatable as the biofilm protects against antibiotics and host immunity. A major barrier to developing new antimicrobials is the lack of in vivo biofilm models. Standard microbiological testing is usually performed in vitro using planktonic bacteria, without representation of biofilms, reducing translatability. Here we develop tools to study both infection and biofilm formation by P. aeruginosa in vivo to accelerate development of strategies targeting infection and pathogenic biofilms. Methods: Biofilms were quantified in vitro using Crystal Violet staining and fluorescence biofilm assays. For in vivo assays, C. elegans were infected with P. aeruginosa strains. Pathogenicity was quantified by measuring healthspan, survival and GFP fluorescence. Healthspan assays were performed using the WormGazerTM automated imaging technology. Results: Using the nematode Caenorhabditis elegans and P. aeruginosa reporters combined with in vivo imaging we show that fluorescent P. aeruginosa reporters that form biofilms in vitro can be used to visualize tissue infection. Using automated tracking of C. elegans movement, we find that that the timing of this infection corresponds with a decline in health endpoints. In a mutant strain of P. aeruginosa lacking RhlR, a transcription factor that controls quorum sensing and biofilm formation, we find reduced capacity of P. aeruginosa to form biofilms, invade host tissues and negatively impact healthspan and survival. Discussion: Our findings suggest that RhlR could be a new antimicrobial target to reduce P. aeruginosa biofilms and virulence in vivo and C. elegans could be used to more effectively screen for new drugs to combat antimicrobial resistance.

An Integrated Microfluidic Platform for Evaluating in Vivo Antimicrobial Activity of Natural Compounds Using a Whole-Animal Infection Model.

Real-time Monitoring of Immune Responses under Pathogen Invasion and Drug Interference by Integrated Microfluidic Device Coupled with Worm-Based Biosensor.

An automated microfluidic platform for toxicity testing based on Caenorhabditis elegans

A microfluidic device for whole-animal drug screening using electrophysiological measures in the nematode C. elegans

Pseudomonas aeruginosa infected nematode-on-a-chip model array for antibacterials screening

An Efficient and Novel Screening Model for Assessing the Bioactivity of Extracts Against Multidrug-Resistant Pseudomonas Aeruginosa Using Caenorhabditis Elegans.

Development of an integrated microfluidic device for evaluating of in vivo chemo-sensing of intact Caenorhabditis elegans

A high-throughput microplate toxicity screening platform based on Caenorhabditis elegans

Primary exploration of host–microorganism interaction and enteritis treatment with an embedded membrane microfluidic chip of the human intestinal–vascular microsystem

New tools to monitor Pseudomonas aeruginosa infection and biofilms in vivo in C. elegans

Establishment of Antimicrobial Screening Experiment System for Caenorhabditis Elegans

A Microfluidic Platform for Longitudinal Imaging in Caenorhabditis elegans

A microfluidic microwell device operated by the automated microfluidic control system for surface-enhanced Raman scattering-based antimicrobial susceptibility testing

A Microfluidic Device for Rapid Screening of Chemotaxis-Defective Caenorhabditis Elegans Mutants

Recent progress of Caenorhabditis elegans:as host model and tool for antimicrobial drug screening

Advances in C. elegans behavior research with microfluidic devices and its future prospects in the evaluation of exogenous pollutants

Worms on a Chip

A Microfluidic Device for the Continuous Culture and Analysis of Caenorhabditis Elegans in A Toxic Aqueous Environment

Dual-modal Detection of Antimicrobial Susceptibility in Pathogenic Bacteria Based on the High-Throughput Microfluidic Platform

Automatic Membrane-Based Microfluidic Platform for Investigating the Emergence of Pathogenicity

Implementation of Microfluidics for Antimicrobial Susceptibility Assays: Issues and Optimization Requirements